Skip to main content

Advertisement

Table 1 Background of ACA+ and ACA- SS patients in this study

From: Anti-centromere antibody-seropositive Sjögren's syndrome differs from conventional subgroup in clinical and pathological study

  ACA (+) ACA (-) P value
N (M/F) 14 (0/14) 48 (1/47) 0.59
Age 57.4 ± 9.6 58.3 ± 13.2 0.82
Follow-up period (year) 6.6 ± 5.6 4.5 ± 4.6 0.16
Raynaud's phenomenon 8/13 (61.5%) 4/48 (8.3%) 1.86 × 10-5
anti-SS-A/Ro Ab or anti-SS-B/La Ab 0/14 (0.0%) 37/48 (77.1%) 2.30 × 10-7
IgG (mg/dl) 1530.2 ± 267.1 2056.0 ± 730.2 0.018
Average of FS 1.4 ± 1.0 2.3 ± 1.6 0.035
  1. Clinical characteristics of the ACA-seropositive and non-ACA Sjögren's syndrome (SS) patients are shown. The differences were calculated using Student's t test and the Chi-square test. (*; p < 0.05; statistically significant). The differences found regarded the prevalence of Raynaud's phenomenon, the level of IgG and the average of FS.
  2. Follow-up period is duration from point of diagnosis. ACA; anti-centromere antibody, FS; focus score